CETA itself will not create new jobs. What we worked hard to do was to ensure that these excessive demands that were being put on our intellectual property system on pharmaceuticals did not ruin the Canadian generic pharmaceutical industry.
As I said, I think the mitigating factors are important. We have an export exception, so that during the period of extension—again, the implementation will be crucial—we will be able to develop a product, submit it to Health Canada for approval, and get approval.
We won't be able to sell it in Canada until the patents expire, but during that period we could export it to other markets. We're hoping that with that, our industry will continue to flourish in Canada.